BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Bayforest Capital Ltd

Bayforest Capital Ltd lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 87.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,479 shares of the biotechnology company’s stock after selling 61,552 shares during the period. Bayforest Capital Ltd’s holdings in BioCryst Pharmaceuticals were worth $66,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Focus Partners Wealth acquired a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at $77,000. Farther Finance Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 326.8% during the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 8,109 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the period. Vestmark Advisory Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals in the third quarter worth about $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at about $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 2.8%

Shares of BioCryst Pharmaceuticals stock opened at $8.76 on Friday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.31. The stock has a market cap of $2.20 billion, a PE ratio of 7.30 and a beta of 0.70. The company’s 50-day moving average price is $8.80 and its two-hundred day moving average price is $7.70.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The company had revenue of $163.28 million during the quarter, compared to analyst estimates of $151.32 million. During the same quarter last year, the firm posted ($0.13) EPS. The business’s revenue for the quarter was up 209.1% on a year-over-year basis. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post 0.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on BCRX shares. Royal Bank Of Canada dropped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Evercore initiated coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price objective for the company. Finally, Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Ten equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.64.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the transaction, the insider owned 400,703 shares in the company, valued at approximately $3,666,432.45. The trade was a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.